LY2228820 化学構造
分子量: 612.74



Quality Control & MSDS


  • Compare p38 MAPK Inhibitors
    p38 MAPK製品生物活性の比較
  • 研究分野



製品説明 LY2228820は、p38 MAPKの新しくて強力な阻害剤で、 IC50 が7 nMになる。
ターゲット p38α
IC50 7 nM [1]
In vitro試験 LY2228820 inhibits p38α, as well as the level of phosphoMAPKAPK-2 (pMK2) in RAW 264.7 cells, with IC50 values of 7 nM and 34.3 nM, respectively. Furthermore, LY2228820 inhibits lipopolysaccharide (LPS)-induced TNFα formation in murine peritoneal macrophages, with IC50 of 5.2 nM. [1] In multiple myeloma (MM) cells, including INA6, RPMI-8226, U266, and RPMI-Dox40, LY2228820 (200 nM–800 nM) significantly blocks p38MAPK signaling, as revealed by its inhibition on phosphorylation of HSP27, a downstream target of p38MAPK, without affecting the expression level of HSP27. LY2228820 (200 nM–400 nM) enhances bortezomib-induced cytotoxicity and apoptosis, but LY2228820 alone doesn't inhibit the growth of MM.1S cells. LY2228820 (200 nM–800 nM) also inhibits secretion of IL-6 and MIP-1α in long-term BM stromal cells (LT-BMSCs), BM mononuclear cells (BMMNCs), peripheral blood (PB) CD138+, CD138 or PB CD14+ cells. LY2228820 (400 nM–800 nM) also blocks osteoclastogenesis from CD14+ cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
RPMI-8226 NGDs[FRMcW6jc3WgZZN{[Xl? MkmwglgxOCCwTR?= NVPCNlJPTE2VTx?= MnfQbY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGhUWDJ5 MoTKNVg{QTd|NEW=
U266 NVHRPWl5U2mwYYPlJIF{e2G7 MXz+PFAxKG6P M{LKbmROW09? NGL6OZhqdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhUFOSMke= MX:xPFM6PzN2NR?=
MM.1S M1\0bWtqdmG|ZTDhd5NigQ>? M1rte545ODBibl2= NXfrXXZ7TE2VTx?= M1zNdolvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBJW1B{Nx?= NULISVFNOTh|OUezOFU>
RPMI-Dox40 NFrHbJBMcW6jc3WgZZN{[Xl? NUXJVHhxhjhyMDDuUS=> MX;EUXNQ MWXpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gTHNROjd? MonkNVg{QTd|NEW=
RPMI-LR5 M3Xkd2tqdmG|ZTDhd5NigQ>? MlzCglgxOCCwTR?= M331PWROW09? Ml;nbY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGhUWDJ5 NVG0fW57OTh|OUezOFU>
INA-6 MWnLbY5ie2ViYYPzZZk> NXq3c2pxhjhyMDDuUS=> MljESG1UVw>? M{WyXIlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBJW1B{Nx?= MmLxNVg{QTd|NEW=
RPMI-8226 MYXDfZRwgGmlaYT5JIF{e2G7 NELFOW9,OTByMDDuUS=> NGjM[|ZFVVOR MkDMco8he2mpbnnmbYNidnRiY4n0c5RwgGmlaYT5 M2jxOFE5Ozl5M{S1
U266 M{eydmN6fG:6aXPpeJkh[XO|YYm= M1;ab54yODByIH7N NE[3XIZFVVOR MXjuc{B{cWewaX\pZ4FvfCCleYTveI95cWOrdIm= M4i2SFE5Ozl5M{S1
MM.1S MmHFR5l1d3irY3n0fUBie3OjeR?= MXn+NVAxOCCwTR?= MkXRSG1UVw>? M1X2NI5wKHOrZ37p[olk[W62IHP5eI91d3irY3n0fS=> MX6xPFM6PzN2NR?=
RPMI-Dox40 MYLDfZRwgGmlaYT5JIF{e2G7 MnHXglExODBibl2= Mk\ySG1UVw>? MmLuco8he2mpbnnmbYNidnRiY4n0c5RwgGmlaYT5 NV3veFFxOTh|OUezOFU>
RPMI-LR5 NWXrO3FCS3m2b4jpZ4l1gSCjc4PhfS=> NX61RmdqhjFyMECgcm0> Mmi2SG1UVw>? MVPuc{B{cWewaX\pZ4FvfCCleYTveI95cWOrdIm= MVSxPFM6PzN2NR?=
INA-6 MWLDfZRwgGmlaYT5JIF{e2G7 Mn;KglExODBibl2= MnnpSG1UVw>? NUjoXmZNdm9ic3nncolncWOjboSgZ5l1d3SxeHnjbZR6 NWi3Zo1POTh|OUezOFU>
CD14+ NYrsZmJQTnWwY4Tpc44h[XO|YYm= MnLtglgxOCCwTR?= MVvEUXNQ MXHpcohq[mm2czDvd5Rmd2OuYYP0c4dmdmW|aYOg[pJwdSCFREG0JJBwe2m2aY\lJINmdGy| NH3DflAyQDN7N{O0OS=>
U-87-MG NGO3Z25HfW6ldHnvckBie3OjeR?= NVLiVnlxOSEQvF2= M4rPPGROW09? NGfrUYxz\WS3Y3XzJJR2dW:{LXTybZZmdiClb4LkJIZwem2jdHnvci=> M2P4[FI{OzN3NUC2
MDA-MB-231 MlnESpVv[3Srb36gZZN{[Xl? NYTPXI8{OSEQvF2= M3PUR2ROW09? Ml;idoVlfWOnczD0eY1wei2mcnn2[Y4h[2:{ZDDmc5Ju[XSrb36= MUeyN|M{PTVyNh?=
A-2780 NX3Vcot1TnWwY4Tpc44h[XO|YYm= NVm0cpU4OSEQvF2= M2jNfWROW09? NHvlZXRz\WS3Y3XzJJR2dW:{LXTybZZmdiClb4LkJIZwem2jdHnvci=> NX3ybJg3OjN|M{W1NFY>
SK-OV-3 NFnWSHpHfW6ldHnvckBie3OjeR?= MUWxJO69VQ>? NV7oeHF6TE2VTx?= MnP3doVlfWOnczD0eY1wei2mcnn2[Y4h[2:{ZDDmc5Ju[XSrb36= MU[yN|M{PTVyNh?=
LXFA-629 MoLqSpVv[3Srb36gZZN{[Xl? Ml\GNUDPxE1? MnTmSG1UVw>? M2HZbJJm\HWlZYOgeJVud3JvZILpeoVvKGOxcnSg[o9zdWG2aX;u MUmyN|M{PTVyNh?=
NCI-H1650 MX;GeY5kfGmxbjDhd5NigQ>? M3:zXVEh|ryP MUHEUXNQ NVzC[mYzemWmdXPld{B1fW2xcj3kdol3\W5iY3;y[EBnd3KvYYTpc44> NYi1Xo9UOjN|M{W1NFY>
PC-3 NHTKcnlHfW6ldHnvckBie3OjeR?= MV:xJO69VQ>? NEHIW4pFVVOR MXLy[YR2[2W|IIT1cY9zNWS{aY\lckBkd3KmIH\vdo1ifGmxbh?= MYGyN|M{PTVyNh?=
RAW264.7 Ml\WSpVv[3Srb36gZZN{[Xl? M4TiOZ4zOCEQvF2= NGPQPJNFVVOR M{WxdolvcGmkaYTzJGFvcXOxbYnjbY4ue3SrbYXsZZRm\CCPS{KgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA{PS5|IH7N MmftNlQ{PTZ6MUS=
mouse peritoneal macrophages NVrkcHY2TnWwY4Tpc44h[XO|YYm= M{jzbJ4zOCEQvF2= NVSwVHk6TE2VTx?= NGfudJlNWFNxSV\OMe6{6oDVc4TpcZVt[XSnZDDUUmYu|rFicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhPi5|IH7N MWCyOFM2PjhzNB?=
A549 MX7GeY5kfGmxbjDhd5NigQ>? MoHQglIxKM7:TR?= NGP3elNFVVOR NWPQUpBYcW6qaXLpeJMhVFCVLXnu[JVk\WRiQ2jDUFgheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNVQ1Njlibl2= Mn7TNlQ{PTZ6MUS=
MDA-231 MUnGeY5kfGmxbjDhd5NigQ>? NGDuOG9,OTBizszN NHTmcIN{fXCycnXzd4V{KESNSz2xJIV5eHKnc4Ppc44> MkTINlY1ODd6NEO=
MCF-7 MVzGeY5kfGmxbjDhd5NigQ>? MUL+NVAh|ryP M2\LXJN2eHC{ZYPz[ZMhTEuNLUGg[ZhxemW|c3nvci=> MoXZNlY1ODd6NEO=
MDA-435 NGnoR2tHfW6ldHnvckBie3OjeR?= NGPZdox,OTBizszN MXvzeZBxemW|c3XzJGRMUy1zIHX4dJJme3Orb36= MnHVNlY1ODd6NEO=
PC3 NXfqSoZ7TnWwY4Tpc44h[XO|YYm= M{DwVJ4yOCEQvF2= M1\JfmROW09? MYDzeZBxemW|c3XzJGRMUy1zIHX4dJJme3Orb36= NX3sRphKOjZ7MUO2NFg>

... Click to View More Cell Line Experimental Data

In vivo試験 In LPS-induced mice, LY2228820 effectively inhibits the formation of TNFα with a threshold minimum 50% effective dose (TMED50) less than 1 mg/kg. In a rat model of collagen-inducedarthritis (CIA), LY2228820 displays potent effects on paw swelling, bone erosion, and cartilage destruction, with a threshold minimum 50% effective dose (TMED50)of 1.5 mg/kg. [1]
臨床試験 LY2228820 is currently under a Phase I clinical trial for the treatment of advanced cancer.

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Inhibition of p38α Inhibition of p38α is determined using recombinant human p38α in a standard filter binding protocol using ATP[γ-33P] and EGFR 21-mer peptide as substrate. Functional inhibition of TNFα in murine peritoneal macrophages is determined using LPS stimulation in the presence of LY2228820. To assess p38α activity in cells more directly, RAW 264.7 cells are treated with LY2228820 and then stimulated with anisomycin. The level of p38α activity is detected using a phosphoMAPKAPK-2 (pMK2) (Thr 334) antibody which reacts with a residue specifically phosphorylated by p38α.

細胞アッセイ: [2, 3]

細胞株 MM cells, including INA6, RPMI-8226, U266, and RPMI-Dox40
濃度 200 nM–800 nM
反応時間 48 hours
実験の流れ MTT assays and APO 2.7 staining are performed to assess cellular proliferation and induction of apoptosis, respectively. Viability is expressed as percent viable cells. Apoptosis in cells is evaluated by APO 2.7 staining. For detection of mitochondrial membrane protein 7A6 expressed in apoptotic cells, cells are incubated with APO 2.7 reagent for 20 min. Expression of APO 2.7 is determined using an EPICS XL flow cytometer.

動物実験: [1]

動物モデル Lipopolysaccharide (LPS)-induced Balb/c mice
製剤 Dissolved in 1% CMC/0.25% Tween 80 in water
投薬量 0–20 mg/kg
投与方法 Oral bid dosing for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download LY2228820 SDF
分子量 612.74


CAS No. 862507-23-1
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 4 mg/mL warming (6.52 mM)
100 mg/mL warming (163.2 mM)
エタノール 3 mg/mL (4.89 mM)
In vivo Saline 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 5-(2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate

文献中の引用 (9)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related p38 MAPK 阻害剤

  • Pexmetinib (ARRY-614)

    Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.

  • SB239063

    SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.

  • GDC-0994

    GDC-0994 is a potent, orally available ERK1/2 inhibitor. Phase 1.

  • Ulixertinib (BVD-523, VRT752271)

    Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.

  • SB203580


    Features:First reported p38 inhibitor.

  • BIRB 796 (Doramapimod)

    BIRB 796 (Doramapimod)はp38αMAPKの高さ選択阻害剤、THP-1細胞に作用する時、EC50が18nMになる。

    Features:The first p38 MAPK inhibitor to be tested in a phase III clinical trial.

  • SB202190 (FHPI)

    SB202190 (FHPI)は、p38α</b、p38βを目標としている強力なp38 MAPK阻害剤で、IC50 がそれぞれ 50 nM と 100 nMです。

  • Losmapimod (GW856553X)

    Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3.

  • PH-797804



Tags: LY2228820を買う | LY2228820供給者 | LY2228820を購入する | LY2228820費用 | LY2228820生産者 | オーダーLY2228820 | LY2228820代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID